Prediction and Mapping of Intraprostatic Tumor Extent with Artificial Intelligence.

Alan Priester^1,2, Richard E Fan³, Joshua Shubert², Mirabela Rusu⁴, Sulaiman Vesal³, Wei Shao^4,5, Yash Samir Khandwala³, Leonard S Marks¹, Shyam Natarajan^1,2, Geoffrey A Sonn^3,4

¹Department of Urology, David Geffen School of Medicine, Los Angeles, CA, USA.

²Avenda Health, Inc., Culver City, CA, USA.

³Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.

⁴Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.

⁵Department of Medicine, University of Florida, Gainesville, FL, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Magnetic resonance imaging (MRI) underestimation of prostate cancer extent complicates the definition of focal treatment margins. OBJECTIVE: To validate focal treatment margins produced by an artificial intelligence (AI) model. DESIGN SETTING AND PARTICIPANTS: Testing was conducted retrospectively in an independent dataset of 50 consecutive patients who had radical prostatectomy for…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.